JNJ (JNJ) Makes Investors Think Following Q2 Beat as FY11 Outlook Maintained
Tweet Send to a Friend
Get Alerts JNJ Hot Sheet
Price: $86.36 +0.85%
EPS Growth %: +5.1%
Financial Fact:
Gross profit: 11.95B
Today's EPS Names:
CO, JW-A, FDS, More
EPS Growth %: +5.1%
Financial Fact:
Gross profit: 11.95B
Today's EPS Names:
CO, JW-A, FDS, More
Trade JNJ Now!
Johnson & Johnson (NYSE: JNJ) is trading modestly higher this morning, as the company bested second-quarter expectations, but simply reaffirmed its outlook.
Global sales in the quarter increased 8.3 percent, or 5.7 percent on a constant-currency basis, to $16.597 billion. The number beat Street views calling for $16.22 billion.
Net income in the quarter grew 4.9 percent to $3.548 billion, or $1.28 per share, topping views calling for earnings of $1.23 per share.
Net margin consolidated somewhat in the quarter, from 22.1 percent to 21.4 percent.
Johnson & Johnson's OTC/Nutritionals segment recorded the largest relative loss in the quarter, dropping 11.5 percent to $1.083 billion. Skin Care made the biggest relative gain, jumping 5.3 percent to $929 million.
"Our recently launched pharmaceutical products continued to achieve strong growth and contributed to our solid second quarter results," commented CEO William C. Weldon. "We received several new product approvals across our businesses which will benefit patients around the world and drive future growth."
Fiscal 2011 guidance was maintained, calling for earnings of $4.90 to $5.00 per share which compares to the consensus of $4.95.
Johnson & Johnson shares are up about 0.2 percent pre-market Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Global sales in the quarter increased 8.3 percent, or 5.7 percent on a constant-currency basis, to $16.597 billion. The number beat Street views calling for $16.22 billion.
Net income in the quarter grew 4.9 percent to $3.548 billion, or $1.28 per share, topping views calling for earnings of $1.23 per share.
Net margin consolidated somewhat in the quarter, from 22.1 percent to 21.4 percent.
Johnson & Johnson's OTC/Nutritionals segment recorded the largest relative loss in the quarter, dropping 11.5 percent to $1.083 billion. Skin Care made the biggest relative gain, jumping 5.3 percent to $929 million.
"Our recently launched pharmaceutical products continued to achieve strong growth and contributed to our solid second quarter results," commented CEO William C. Weldon. "We received several new product approvals across our businesses which will benefit patients around the world and drive future growth."
Fiscal 2011 guidance was maintained, calling for earnings of $4.90 to $5.00 per share which compares to the consensus of $4.95.
Johnson & Johnson shares are up about 0.2 percent pre-market Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- La-Z-boy, Inc. (LZB) Tops Q4 EPS by 5c
- Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
- Medivation (MDVN) Decline Tied to J&J (JNJ) / Aragon Deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
